GUIDE 04 / SEXUAL DESIRE AND HEALTH
Who reported improvement in desire with PT-141?
Trials found improved desire in women distressed by low interest in sex before menopause. Menopause is when monthly periods have ended. Approval covers a specific condition, so the results cannot settle every concern about sex.
The short version: improved desire in a specific group of women
Who has evidence that PT-141 helps? The main studies involved women before menopause with lasting, distressing loss of sexual desire. Bremelanotide is the medicine's name. The medicine changes activity in parts of the brain linked to desire. Approval covers desire that used to be normal but became low and troubling [22]. The loss occurs across partners, sexual activities, and settings. Approval doesn't extend to every sexual concern or a brief loss of interest.
Your doctor needs to establish the problem before weighing evidence for this medicine.
Women in the trials reported better desire and less distress about low interest [20]. Another study found brain-scan changes while women viewed pictures meant to stir sexual interest [19]. A scan cannot by itself show a benefit noticed in daily life. Nausea, headache, and flushing, a hot and reddened face, were common harms. The prescribing label warns that blood pressure may rise briefly [21][22]. The doctor can consider possible causes, current medicines, and heart health before discussing treatment.
Acts in brain cells while research bottles remain untested
Bremelanotide contains seven amino acids, small substances that also combine to form proteins. The parts are joined to form a ring. That shape affects how the medicine attaches to brain cells and changes their activity. Those cells are involved in interest in sex. The ring's shape does not itself show a benefit or safe treatment. Its main action concerns the brain; increasing blood flow is not the main effect.
For your health, the name alone cannot show what a research bottle contains.
The bremelanotide studies tested a prescription medicine made under drug rules. Bottles described as “PT-141 research chemical” are offered for laboratory tests, without approval as treatment. Those bottles may have unknown contents or strength, or contain unwanted substances. Their labels cannot show who used the contents or how. Studies of the approved medicine don't show the safety of such bottles. The person receiving the substance and the exact product both matter.
Separates women's desire reports from scans and hamster tests
Researchers tested 31 women before menopause who were distressed by low desire [19]. On separate visits, each woman received bremelanotide and placebo, which contained no active medicine. That allowed comparison of each woman's answers after the two treatments. Women reported more desire after receiving the medicine. Scans also showed changes in brain activity while women viewed material intended to stir sexual interest. The answers concerned desire; the scans concerned brain activity. These results describe those women, rather than everyone troubled by a sexual problem.
Your symptoms may have a different cause from the loss of desire studied here.
Bremelanotide is thought to affect desire and arousal, the body's physical response to sexual interest. Medicines that mainly relax blood vessels work differently. This study doesn't prove a direct increase in testosterone, a hormone involved in sex and other functions. In 2025, researchers tested whether hamsters found sex more rewarding after bremelanotide [18]. Researchers checked whether hamsters returned more often to the area associated with sex. A greater preference would suggest that sex had become more rewarding. The hamsters showed no greater preference after receiving the drug. That result questions a proposed explanation in hamsters, without deciding whether women benefit.
Found better desire answers but did not establish benefit for everyone
Two Phase 3 trials, large studies before approval, included 1,267 women with troubling low desire [20]. The women had not reached menopause. During 24 weeks, the medicine group reported better desire and less distress than the placebo group. Placebo had no active drug. Researchers asked about sexual interest and how upsetting its loss had become. The differences were larger than would readily be expected from chance alone. That finding doesn't tell you whether every woman noticed a worthwhile change in daily life.
Knowing they received treatment may affect how people judge later improvement.
A 52-week follow-up included 684 participants who knew they were receiving the medicine [21]. Women continued to report better desire. The follow-up did not identify an additional safety problem. Without a comparison to placebo, expectations could affect the reported changes. Nausea, flushing, and headache were the main drug-related harms. The approved use remains limited to the specified desire condition [22]. The label excludes people whose high blood pressure is uncontrolled or who have diagnosed heart or blood-vessel disease. These trials cannot show the same benefits for men, women after menopause, or other causes of low desire.
Names reported experiences alongside pressure and skin warnings
These accounts describe people experimenting on themselves outside the trials, called research use here. The people describe personal experiences, without a controlled study comparing treatments. Researchers haven't checked these accounts in a trial. Accounts describe more interest in sex, stronger physical responses, or greater sensitivity. Some people say orgasm became easier. Some men describe erections occurring without sexual activity, while other people report no benefit. Nausea appears most often in the accounts. Reports also mention headache, flushing, tiredness, tingling, soreness where a shot entered, or darker skin. The accounts cannot show product origins or what caused a change.
Your blood pressure and heart history matter when considering any hoped-for benefit.
The longer study most often found nausea, flushing, and headache linked with the drug [21]. The prescribing label warns of a brief increase in blood pressure after treatment. Use is ruled out when high blood pressure is uncontrolled or heart or blood-vessel disease is diagnosed [22]. With repeated use, patches on the skin or inside the mouth may become darker [22]. Low desire can also involve pain, relationships, mental health, hormones, and other medicines. Hormones carry messages through the body. A doctor can investigate those causes rather than assume that this drug answers the problem.
Distinguishes low desire from pain and erection problems
PT-141 trials concern women before menopause distressed by reduced sexual interest. The studies cannot show benefits for men or people with different sexual problems. Acting in the brain does not make a drug useful for every problem involving sex. Approval also remains narrow when someone outside the studied group reports an improvement. Your doctor can investigate the concern before deciding whether the trials apply.
Pain during sex, reduced desire, and trouble with erections call for different checks.
The doctor can ask about symptoms, medicines, and heart health as part of that assessment. What would count as a useful improvement in your daily life also matters. A study is more relevant when the problem and people tested resemble the person seeking care. The different health findings explains why these desire trials cannot answer questions about weight, skin, or NAD+ supplements.